Web
Analytics
The news is by your side.

Novartis

Novartis, Pfizer join forces on potentially lucrative fatty liver disease

ZURICH/NEW YORK: Novartis and Pfizer are teaming up to develop treatments for a liver disease many drug companies believe will become a hugely lucrative market, as it is tied to the obesity and diabetes epidemics. The Swiss and US drugmakers announced on Monday that they will collaborate to develop combination therapies involving medicines they have been working on separately to treat nonalcoholic steatohepatitis, or NASH. Though hardly a household name, the progressive fatty liver disease with no approved treatments…

Novartis hopeful for novel heart drug, despite ‘modest’ benefit

ZURICH: Novartis will seek regulatory approval this year for a new kind of anti-inflammatory heart drug, though some experts fear fatal infection risks and a high price may overshadow the medicine’s limited benefits. Keenly awaited clinical trial results released on Sunday showed heart-attack survivors on one of three doses of canakinumab were 15 percent less likely to suffer another major cardiac event than those on a placebo. Novartis had said in June that the drug met its goal in the study but details were only…

Trump pushes drugmakers for lower prices, more U.S. production

WASHINGTON/LOS ANGELES: U.S. President Donald Trump on Tuesday met with top executives from some of the biggest drugmakers, calling on them to boost U.S. production and lower prices, while he also promised to speed up approval times for new medicines. Trump reiterated that the government was paying too much for medicines in its health programs for older, disabled and poor people and said he would soon appoint a new U.S. Food and Drug Administration leader. At the same time, the meeting between Trump and the…

Novartis says 82 percent of leukemia patients in remission after CAR-T

BASEL, Switzerland: An experimental cancer therapy being developed by Novartis AG eliminated an aggressive form of blood cancer in 82 percent of children and young adults treated with modified immune cells in a mid-stage trial, the company said on Saturday. Interim results from the multi-center trial for 50 patients with acute lymphoblastic leukemia whose cancer returned or did not respond to other treatment, showed that 41 were disease-free three months after treatment with the drug, called CTL019. The trial results…

Novartis backs off from 2016 date for testing Google autofocus lens

NEW YORK: Novartis has abandoned a 2016 goal to start testing its autofocus contact lens on people, though it said the groundbreaking product it is making with internet giant Google is "progressing steadily." "It is too early to say when exactly human clinical trials for these lenses will begin," a spokeswoman for the Basel-based drugmaker said in an email on Friday. "This is a very technically complex process and both sides are learning as we go along. We will provide updates at the appropriate time," she said.…